Circulating HLA-G and its association with cardiovascular markers in pregnancy by Lekva, T. et al.
Journal of Reproductive Immunology 146 (2021) 103331
Available online 19 May 2021
0165-0378/© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Short communication 
Circulating HLA-G and its association with cardiovascular markers 
in pregnancy 
Tove Lekva a,b,*, Daniel P. Jacobsen a, Meryam Sugulle a, Kjartan Moe a,c, Heidi E.S. Fjeldstad a,d, 
Ralf Dechend e,f, Anne Cathrine Staff a,d 
a Division of Obstetrics and Gynaecology, Oslo University Hospital, Norway 
b Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Norway 
c Department of Obstetrics and Gynaecology, Bærum Hospital, Vestre Viken Hospital Trust, Norway 
d Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Norway 
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A B S T R A C T   
Human Leukocyte Antigen-G (HLA-G) prevents the activity of immune cells and is decreased in women with 
preeclampsia. We aimed to investigate the associations between circulating soluble HLA-G (sHLA-G) and 92 
cardiovascular disease-related biomarkers from a previously published multiplex study in women with pre-
eclampsia and controls. We found 15 markers significantly associated with circulating sHLA-G in univariate 
analyses. After multivariable adjusted regression, only proto-oncogene tyrosine-protein kinase Src (SRC) and 
vascular endothelial growth factor D were significantly associated with sHLA-G. Low SRC, previously observed in 
the circulation of preeclamptic women, may be regulated by low sHLA-G, and reflect decreased trophoblast 
differentiation and syncytical formation.   
1. Introduction 
Human Leukocyte Antigen-G (HLA-G) prevents the activity of im-
mune cells and may protect the fetus from damage by the maternal 
immune system. It is expressed in various cell types and is implicated in 
a diverse array of pathological settings, such as autoimmune disease, 
viral infection, cancer and organ transplantation (Carosella et al., 2015). 
The HLA-G molecule binds to several receptors, like the inhibitory 
immunoglobulin-like transcript 2 receptor (ILT2), ILT4 and killer cell 
immunoglobulin-like receptor 2DL4, to down-regulate the immune 
response via both indirect and direct mechanisms (Persson et al., 2019). 
In pregnancy, HLA-G is expressed on extravillous trophoblast cells at the 
feto-maternal interface in the placenta, decidua and the uterus. Soluble 
isoforms of HLA-G (sHLA-G) can also be detected in maternal blood and 
the levels are highest in the first trimester (Steinborn et al., 2007). 
Previous research has shown that women with preeclampsia have 
reduced blood levels of sHLA-G and reduced expression of HLA-G in 
extravillous trophoblasts of the placenta (Persson et al., 2019). 
In the present study, we aimed to investigate the associations be-
tween circulating sHLA-G in pregnancy and 92 circulating 
cardiovascular disease (CVD)-risk biomarkers from a multiplex panel. 
We selected a cohort of women with preeclampsia and controls, to 
further investigate the epidemiological association of preeclampsia and 
future CVD (Lekva et al., 2020). 
2. Material and methods 
2.1. Subjects 
Pregnant women scheduled for elective caesarean section were 
recruited between 2001 and 2014 to the Oslo Pregnancy Biobank. The 
Regional Committee for Medical and Health Research Ethics in South- 
Eastern Norway approved the study. All women signed informed con-
sent. Preeclampsia was defined as new-onset hypertension (blood 
pressure ≥140/90 mmHg) and proteinuria (≥1+ on dipstick or ≥30 
total protein/creatinine ratio) at ≥20 weeks’ gestation. Early-onset 
preeclampsia was defined as delivery prior to 34 weeks’ gestation, 
whereas late-onset preeclampsia as delivery ≥ 34 weeks’ gestation. 
Clinical characteristics of the cases and controls have been previously 
published (Lekva et al., 2020). In summary, maternal age, parity and 
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smoking rates were similar between the groups, whereas body mass 
index (BMI) and blood pressure at <20 weeks’ gestation were signifi-
cantly higher, and gestational age at sampling was significantly lower in 
the preeclampsia groups as compared to the control group. 
2.2. Multiplex biomarker analysis and soluble HLA-G analysis 
EDTA plasma samples from normotensive controls (n = 49), early- 
onset preeclampsia(n = 37) and late-onset preeclampsia (n = 29) were 
analyzed using the Proseek multiplex CVD I Olink assay at the Clinical 
Biomarkers Facility, Science for Life Laboratory, Uppsala, Sweden, tar-
geting 92 CVD linked biomarkers, as previously published (Lekva et al., 
2020). Circulating sHLA-G was measured in duplicate using commer-
cially available antibodies (BioVendor Laboratory Medicine Inc., Brno, 
Czech Republic), as previously described (Jacobsen et al., 2020). 
2.3. Statistics 
Statistical analyses were performed using SPSS Statistics 25.0 (IBM). 
To identify the CVD biomarkers with the strongest associations with 
circulating sHLA-G, we first conducted univariate analysis for each 
variable. All variables with p < 0.05 were then included in the adjusted 
multivariable stepwise analysis. A p-value <0.05 was considered 
significant. 
3. Results and discussion 
3.1. Circulating soluble HLA-G in normotensive controls and 
preeclampsia 
We found a lower, but not statistically significant (p = 0.268) me-
dian circulating sHLA-G in early-onset preeclampsia [median U/mL 
(25th,75th); [125 (93,188)] as compared to normotensive pregnant 
controls 147 (101, 240)] and late-onset preeclampsia [158 (99, 270)]. 
This lack of a significant difference is in contrast to our findings in our 
larger cohort, in which levels of circulating sHLA-G were significantly 
lower in women with preeclampsia compared to controls (Jacobsen 
et al., 2020). Several previously published papers have also reported low 
sHLA-G in the circulation as well as reduced HLA-G expression in the 
placenta in preeclampsia (Persson et al., 2019). The lacking statistical 
significance in our cohort may be due to a smaller sample size and the 
fact that blood was sampled at an earlier gestational age in preeclamptic 
pregnancies than controls. This could obscure a potential difference 
between diagnosis groups, as sHLA-G decreases by gestational age 
during the latter part of pregnancy (Steinborn et al., 2007). 
3.2. Circulating HLA-G and its association with CVD markers 
We found 15 CVD markers significantly positively associated with 
sHLA-G in univariate linear regression analysis (Table 1). We found no 
interactions between any of the 15 markers and diagnosis (group), with 
sHLA-G as the outcome (not shown). In previously published work 
(Lekva et al., 2020), we found only tumor necrosis factor receptor su-
perfamily member 5 (CD40), proto-oncogene tyrosine-protein kinase Src 
(SRC), interleukin 6 (IL6), kallikrein-11 (hK11) and follistatin (FS) 
significantly different in these 15 markers between the groups (normo-
tensive controls, late-onset preeclampsia and early-onset preeclampsia). 
When including these 15 CVD markers in a multivariable analysis, 
only SRC and endothelial growth factor D (VEGFD) were significantly 
associated with sHLA-G after adjusting for age and BMI. Regarding the 
potential mechanisms behind the association between sHLA-G and SRC 
in our data, we speculate that activation of ILT-4 by sHLA-G results in 
the recruitment of SH2 containing tyrosine phosphatase (SHP)-1 and -2 
(Liang et al., 2008). These phosphatases may, in turn, activate NF-κB 
and downstream IL-6 production, as well as SRC (Walter et al., 1999). 
Interestingly, previous research has shown that SRC plays a role in 
trophoblast differentiation and syncytical formation (Daoud et al., 
2006). In summary, low levels of sHLA-G may lead to less SHP-1 and 2, 
which may result in decreased SRC signaling and potentially reduced 
trophoblast differentiation. In the present study, SRC is measured in 
plasma, but circulating protein levels could reflect the expression levels 
in the placenta or possibly regulate the maternal-fetal interface indi-
rectly. Indeed, a decrease in SRC activation has been found in the pla-
centas of women with preeclampsia, and the downregulation of SRC 
signaling has been suggested as an explanation for the defective 
trophoblast differentiation and invasion leading to abnormal develop-
ment of the placenta in preeclampsia (Irtegun et al., 2017). 
VEGFD, the other protein associated with sHLA-G in the multivari-
able analysis, may promote the growth and remodeling of blood vessels 
and lymphatics by activating endothelial receptors. Binding and acti-
vation of the receptors VEGFR2 or VEGFR3 induces intracellular 
signaling through a variety of mediators including SRC (Pandey et al., 
2018). Thus, reduced VEGFD may lead to lower VEGFR2 and SRC 
signaling. Cytoplasmic SRC may also phosphorylate VEGFR2 and 
initiate downstream signaling, and may result in lower angiogenesis 
when SRC is low. As previously published (Lekva et al., 2020), the 
circulating maternal levels of VEGFD were similar in preeclamptic 
pregnancies compared to controls, while the SRC level was lower in 
preeclamptic women. However, since the VEGFD measured by the Olink 
assay represents the total VEGFD, we do not know how much is bound 
and how much is free (bioactive). As we lack the mechanistic data, it is 
difficult to interpret the importance of VEGFD and its connection to 
sHLA-G, but this should be studied in future research. 
Trophoblast development and tumor progression share similar 
Table 1 
Association of circulating HLA-G and circulating CVD markers in univariate and 
multivariable models for the included pregnancy cohort (n = 115).  
Circulating HLA-G  
Univariate Multivariable 
adjusted* 
Variables Beta P-value Beta P-value 
Maternal age at delivery (years) − 0.02 0.857 − 0.06 0.494 
Body mass index (BMI) early pregnancy 
(kg/m2) 
0.08 0.383 0.09 0.342 
Systolic blood pressure <20 weeks 
(mmHg) 
− 0.01 0.978   
Diastolic blood pressure <20 weeks 
(mmHg) 
0.03 0.775   
Gestational age at delivery and sampling 
(weeks) 
0.15 0.124   
Soluble fms-like tyrosine kinase 1/ 
placental growth factor (sFLT/PlGF) 
ratio 
− 0.14 0.161   
CD40 ligand (CD40 L) 0.29 0.002 − 0.17 0.433 
Tumor necrosis factor receptor 
superfamily member 5 (CD40) 
0.26 0.006 0.09 0.402 
Epidermal growth factor (EGF) 0.27 0.005 − 0.14 0.484 
Proto-oncogene tyrosine-protein 
kinase Src (SRC) 
0.34 <0.001 0.34 <0.001 
Interleukin-6 (IL6) 0.19 0.049 0.12 0.243 
Platelet-derived growth factor subunit B 
(PDGF subunitB) 
0.20 0.037 − 0.08 0.565 
C-X-C motif chemokine 1 (CXCL1) 0.27 0.005 0.05 0.661 
Heat shock 27 kDa protein (HSP27) 0.30 0.002 0.03 0.840 
NF-kappa-B essential modulator (NEMO) 0.26 0.005 − 0.14 0.361 
Platelet endothelial cell adhesion 
molecule (PECAM1) 
0.25 0.010 0.08 0.469 
Kallikrein-11 (hK11) 0.20 0.040 0.14 0.138 
C-C motif chemokine 4 (CCL4) 0.26 0.007 0.17 0.061 
C-C motif chemokine 3 (CCL3) 0.24 0.011 0.16 0.099 
Vascular endothelial growth factor D 
(VEGFD) 
0.19 0.048 0.21 0.021 
Follistatin (FS) 0.21 0.027 0.14 0.146 
*Adjusted for age and BMI. Standardized coefficients Beta are given in the 
multivariable model for significant and adjustment variables and Beta ln for the 
other variables. 
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properties and interestingly the HLA-G/ILT4/VEGF signaling is found 
increased in tumor progression (Garcia et al., 2020; Zhang et al., 2016). 
The reduced trophoblast differentiation and invasion in preeclampsia 
and decreased HLA-G/SRC and potential involvement of VEGF signaling 
strengthens these similarities. 
4. Conclusion 
We aimed to investigate the associations between circulating sHLA-G 
and 92 CVD biomarkers from a previously published Olink study in a 
cohort of early- and late-onset preeclampsia versus controls. We found 
15 markers significantly associated with circulating sHLA-G by univar-
iate regression analysis. In the multivariable adjusted regression anal-
ysis with these 15 biomarkers, only SRC and VEGFD were positively 
associated with sHLA-G. Low SRC, previously observed in the circulation 
of women with preeclampsia, may be regulated by low sHLA-G, and may 
reflect decreased trophoblast differentiation and syncytical formation. 
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